Exploiting the potential of antisense: Beyond phosphorothioate oligodeoxynucleotides

Chemistry and Biology

Volumn 3, Issue 5, 1996, Pages 319-323

  Stein, C A ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE RECEPTOR; HEPARIN; ORGANOPHOSPHORUS COMPOUND;

ARTICLE; DRUG EFFECT; ENDOCYTOSIS; METABOLISM;

ENDOCYTOSIS; HEPARIN; OLIGONUCLEOTIDES, ANTISENSE; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, CELL SURFACE;

EID: 0030132985     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(96)90113-1     Document Type: Note

References (23)

1. Stein, CA & Cheng, Y.-C. (1993). Antisense oligonucleotides: is the bullet really magical? Science 261, 1004-1012.
2. Bayever, E., et al., & Armitage, J. (1993). Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res. Dev. 3, 383-390.
3. Agrawal, S. & Tang, J. (1992). GEM 91: an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res. Dev. 2, 261-266.
4. Methia, N., Louache, F. & Vainchenker, W. (1993). Oligodeoxynucleotides antisense to the protooncogene c-mpl specifically inhibit in vitro megakaryocytopenia. Blood 82, 1395-1401.
5. Stec, W.J., Zon, G., Egan, W. & Stec, B. (1984). Automated solid7 phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106, 6077-6079.
6. 3H-1,2-Benzodithiole-3-one 1,1 -dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112, 1253-1254.
7. Stein, C.A., Subasinghe, C., Shinozuka, K. & Cohen, J. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209-3221.
8. Giles, R.V., Spiller, D. & Tidd, D. (1995). Detection of ribonuclease-H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5, 23-32.
9. 2 derived from diastereomeric O-ethyl phosphorothioates. Nucleic Acids Res. 17, 1549-1561.
10. Stec, W., Grajkowski, A., Koziokiewicz, M. & Uznanski, B. (1991). Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside) phosphorothioates. Nucleic Acids Res. 19, 5883-5888.
11. Dean, N. & McKay, R. (1994). Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 11762-11766.
12. Guvakova, M.A., Yakubov, L.A., Vlodavsky, I., Tonkinson, J. & Stein, C.A. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell-surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
13. Benimetskaya, L., et al., & Stein, C.A. (1995). Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res. 23, 4239-4245.
14. Khaled, Z., et al., & Stein, C.A. (1996). Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 24, 737-745.
15. Simons, M., Edelman, E., DeKeyser, J., Langer, R. & Rosenberg, R. (1992). Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
16. Burgess, T., et al., & Farrell, C. (1995). The antiproliferative activity of c-myb and c-myb antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc. Natl. Acad. Sci. USA 92, 4051-4055.
17. Wang, W., Chen, H., Schwartz, A., Stein, C.A. & Rabbani, L (1996). Sequence-independent inhibition of in vitro vascular smooth muscle proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J. Clin. Invest, in press.
18. Wyatt, J., et al., & Ecker, D. (1994). Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. USA 91, 1356-1360.
19. 3) of human immunodeficiency virus type 1 gp120. Antisense Res. Dev. 3, 19-31.
20. Maltese, J., Sharma, H., Vassilev, L. & Narayanan, R. (1995). Sequence context of antisense RelA/NF-κB phosphorothioates determines specificity. Nucleic Acids Res. 23, 1146-1151.
21. Rappaport, J., et al., & Klotman, P. (1995). Transport of phosphorothioate oligodeoxynucleotides in kidney: implications for molecular therapy. Kidney Int. 47, 1462-1469.
22. Wagner, R., et al., & Froehler, B.C. (1993). Antisense gene inhibition by oligonucleotides containing the C-5 propyne pyrimidines. Science 260, 1510-1513.
23. Gryaznov, S., et al., & Wilson, W. (1995). Oligonucleotide N3′-P5′ phosphoroamidates. Proc. Natl. Acad. Sci. USA 92, 5798-5802.